Get the Stockscreener App
2.08
0.48%
0.01
After Hours:
2.08
Mural Oncology Plc stock is traded at $2.08, with a volume of 83,507.
It is up +0.48% in the last 24 hours and up +25.30% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
83,507
Relative Volume:
0.32
Market Cap:
$36.03M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.48%
1M Performance:
+25.30%
6M Performance:
-44.24%
1Y Performance:
-33.97%
1-Day Range:
$2.07
$2.09
1-Week Range:
$2.07
$2.09
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.08 | 35.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Citadel Group discloses 1.76% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.76% stake in Mural Oncology By Investing.com - Investing.com Nigeria
Form 8.3The Vanguard Group, Inc.: Mural Oncology plc - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, GES, MURA, TZUP on Behalf of Shareholders - GlobeNewswire Inc.
Citadel discloses 1.73% stake in Mural Oncology - Investing.com
Citadel discloses 1.73% stake in Mural Oncology By Investing.com - Investing.com Australia
Trium Capital discloses 10.52% stake in Mural Oncology By Investing.com - Investing.com Australia
Trium Capital discloses 10.52% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.74% stake in Mural Oncology By Investing.com - Investing.com Australia
BlackRock discloses 1.61% stake in Mural Oncology By Investing.com - Investing.com Canada
Is Mural Oncology plc stock a good dividend stockWeekly Trend Report & AI Driven Price Predictions - Lancaster City Council
BlackRock discloses 1.61% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.74% stake in Mural Oncology - Investing.com
Mural Oncology plc Stock Recovery Path — Analyst Breakdown2025 Macro Impact & Consistent Return Investment Signals - beatles.ru
Is Mural Oncology plc showing insider buyingWeekly Market Report & Daily Profit Maximizing Tips - beatles.ru
Pattern Scan Adds Mural Oncology plc to Watchlist2025 Top Gainers & Verified Momentum Stock Ideas - beatles.ru
Is Mural Oncology plc’s ROE strong enoughJuly 2025 Gainers & Daily Momentum Trading Reports - 강소기업뉴스
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com Nigeria
Visual analytics tools that track Mural Oncology plc performanceWeekly Risk Report & Entry Point Confirmation Signals - Newser
Technical signs of recovery in Mural Oncology plc2025 Market WrapUp & Safe Capital Preservation Plans - Newser
What to expect from Mural Oncology plc in the next 30 daysGold Moves & Fast Exit and Entry Strategy Plans - Newser
Sector ETF performance correlation with Mural Oncology plcPortfolio Growth Summary & Daily Growth Stock Tips - Newser
Heatmap analysis for Mural Oncology plc and competitorsQuarterly Portfolio Review & Risk Managed Investment Strategies - Newser
Is Mural Oncology plc vulnerable to short sellersRisk Management & Weekly Hot Stock Watchlists - خودرو بانک
Citadel Group discloses 1.68% stake in Mural Oncology By Investing.com - Investing.com Canada
Will Mural Oncology plc benefit from rising consumer demand2025 Major Catalysts & Advanced Swing Trade Entry Plans - خودرو بانک
Can Mural Oncology plc be the next market leaderEarnings Trend Report & Weekly Stock Performance Updates - خودرو بانک
Is it time to cut losses on Mural Oncology plc2025 EndofYear Setup & Proven Capital Preservation Methods - Newser
Is Mural Oncology plc reversing from oversold territory2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
What institutional flow reveals about Mural Oncology plc2025 Year in Review & Smart Allocation Stock Reports - Newser
Is Mural Oncology plc exposed to currency risksGap Up & Low Risk Profit Maximizing Plans - خودرو بانک
BlackRock discloses 1.62% stake in Mural Oncology By Investing.com - Investing.com Australia
Citadel Group discloses 1.65% stake in Mural Oncology By Investing.com - Investing.com Australia
Citadel Group discloses 1.68% stake in Mural Oncology - Investing.com India
Boston M&A in August Mural Oncology, UWill and scPharmaceuticals - The Business Journals
What technical models suggest about Mural Oncology plc’s comebackJuly 2025 Volume & Trade Opportunity Analysis Reports - Newser
Trium Capital LLP Acquires Significant Stake in Mural Oncology PLC - GuruFocus
Tick level data insight on Mural Oncology plc volatilityTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
BlackRock discloses 1.62% stake in Mural Oncology - Investing.com India
Citadel Group discloses 1.65% stake in Mural Oncology - Investing.com
Mural Oncology plc’s volatility index tracking explainedJuly 2025 Sector Moves & Risk Managed Trade Strategies - Newser
Using AI based signals to follow Mural Oncology plcMarket Sentiment Report & Weekly Momentum Picks - Newser
Can Mural Oncology plc recover in the next quarterWall Street Watch & Low Risk High Reward Ideas - Newser
Using flow based indicators on Mural Oncology plcEarnings Overview Summary & Reliable Price Breakout Alerts - Newser
Using RSI to spot recovery in Mural Oncology plcJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Is Mural Oncology plc stock suitable for long term investing2025 Investor Takeaways & Community Shared Stock Ideas - خودرو بانک
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):